ADIL
Adial Pharmaceuticals, Inc. (NASDAQ)
Healthcare — Biotechnology
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Buy
2.0 / 5
2 analysts
$2.71
+$0.25 (+5.86%)
Target:
$7.00
(158.3%)
Sign in to add ADIL to a watchlist or set price alerts.
Price History
Fundamentals
| Market Cap | $6.04M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.19 |
| EPS (TTM) | $-4.89 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Buy 2.0 |
| Analyst Target | $7.00 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 62.0 |
| Beta | 1.46 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
BULLISHADIL shows predominantly bullish signals based on its fundamentals and technicals.
+
RSI at 62.0 shows positive momentum.
+
Wall Street consensus is "Buy" from 2 analysts.
+
Average analyst target of $7.00 implies 158.3% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report